GLP-1s and Disordered Eating: What Is Known, and What Isn't

The short version

Two different questions get asked as though they were one, and they have different answers.

The first: if you binge, or eat past fullness in a way that distresses you, does a GLP-1 make that better or worse? Here there is a small but reasonably consistent literature, and it leans toward better or unchanged.

The second: can a drug that suppresses appetite feed a restrictive eating disorder in someone vulnerable to one? Here there is almost no evidence at all — a scoping review searching six databases in April 2025 found nine studies in total on GLP-1s in people with current or past eating disorders⁵. That is not reassurance. That is an absence.

A note before the detail, because it is the most important sentence on this page. A GLP-1 is not a treatment for an eating disorder, and nothing below should be read as one. If eating is the thing you think about most, if you are hiding it, or if the number on the scale governs your day, that belongs with a clinician who treats eating disorders — before a weight prescription, not after it.

What happens to binge eating

The largest synthesis is a rapid review published in December 2025 that screened 1,597 records and included 25 studies: two in adolescents (275 participants) and 23 in adults (8,722)¹. Its findings are worth quoting in the flat way it reports them, because the flatness is the point. Binge-eating episodes fell with liraglutide and binge-eating prevalence fell with semaglutide. Binge-eating scores improved with liraglutide compared with placebo in two studies. Food cravings improved in six of seven studies. Two studies reported eating-disorder adverse events; two reported no binge-eating adverse events. The authors conclude that for most people eating behaviours "may improve or remain unchanged" — and that the data are thin enough that a comprehensive assessment of eating behaviour is needed to understand the benefits and risks¹.

The single most relevant trial is also the one most often mis-cited. A 17-week double-blind randomised trial gave liraglutide 3.0 mg or placebo to 27 adults with binge eating disorder and a BMI of 27 or above; 63% were women, mean age 44. Objective binge episodes per week fell by 4.0 on liraglutide and by 2.5 on placebo — a difference that was not statistically significant (p=0.37). Remission rates were 44% and 36%, also not significantly different. What did differ was weight: 5.2% lost on liraglutide versus 0.9% on placebo (p=0.005)². So the honest reading of the one randomised trial in this population is that both groups improved their bingeing, only one group lost weight, and the trial was far too small to separate the two effects. The authors also disclose a pharmacy dispensing error as a significant limitation.

A 2024 review of the pharmacological treatment of binge eating disorder puts the GLP-1 question in its proper context: the drugs it actually recommends for binge eating disorder are lisdexamfetamine and topiramate, and it notes that only lisdexamfetamine is approved for the indication, and only in some countries. On the incretins, it says in as many words that it is currently unclear whether agents like tirzepatide and retatrutide help with binge eating disorder, while noting they have been reported to reduce binge eating in people with obesity or overweight⁷. If bingeing is your primary problem, there is a medicine licensed for it, and it is not this one.

Does treatment make eating-disorder symptoms worse?

The one study that measured this prospectively is an Australian cohort in a publicly funded weight-management programme. Among 666 adults with a BMI of 40 or above, the 59 already taking a GLP-1 at baseline scored no differently on the Eating Disorder Examination-Questionnaire Short, the Kessler distress scale, or the DASS-21 than those who were not. Of 203 people not on a GLP-1 at baseline with twelve-month follow-up, 31 started one; their median weight fell from 131.0 kg to 120.0 kg, and their eating-disorder and distress scores did not change significantly in either direction. Nobody stopped treatment because of eating-disorder symptoms or psychological distress³.

That is a genuinely reassuring result, and it has genuine limits: 31 people, no control group, no randomisation, and a multidisciplinary programme wrapped around every participant — which is not what most people get when they order a prescription online.

The concern nobody has data on

The mechanism that helps a binge is the same mechanism that could reward a restriction. A 2026 clinical spotlight in the International Journal of Eating Disorders makes this argument directly: GLP-1s may hold promise for some people with binge eating or loss-of-control eating, but the same effects that reduce appetite and food preoccupation "may also reinforce restriction, avoidance of regular eating, compulsive weight control, and relapse in vulnerable individuals." Its central complaint is a systems one — that current prescribing pathways often lack systematic eating-disorder screening, multidisciplinary monitoring, and any guidance on telling appropriate appetite reduction apart from emerging eating-disorder psychopathology. Its first proposed priority is routine eating-disorder screening before and during treatment⁴.

What that risk looks like in practice is illustrated by a 2025 case report in BJPsych Open, and it is worth reading closely because of who it happened to. An adolescent girl with atypical anorexia nervosa — the form where fear of weight gain, restriction and over-exercise occur at a body weight within the normal range — was admitted to a paediatric ward with bradycardia and pericardial effusion. During the admission she disclosed that she had been taking semaglutide, prescribed by her GP because she had previously been on the verge of overweight and distressed about her weight. She stopped it after three months and kept losing weight; a 1 kg gain later triggered a panic attack and an eating-disorder ward admission⁶.

One case proves nothing about frequency. What it does show is the failure mode: the prescription was written for weight-related distress in someone at a normal weight, which is a description of an eating-disorder symptom rather than an indication for a weight drug. The authors' conclusion is about prescribing discipline — restrict it to the right indication, with caution and strict follow-up⁶.

What this means for a mother deciding

Screening is not an insult; being asked is a sign of a good service rather than a bad one. Restricting, purging, compulsive exercise or bingeing at any point in your life — including during or after a pregnancy — belongs in the intake conversation, and so does the honest version of why you want the drug. A programme that never asks is the one to worry about, and our guide to choosing a GLP-1 provider covers what a real intake should include.

While you are on treatment, the signals to raise promptly are these: skipping meals because you can, feeling pleased about not eating rather than simply less hungry, distress at any weight regain, or thoughts about food and weight taking up more of your day rather than less. Any of those warrants a call to your clinician — and, if they are not equipped for it, a referral to someone who treats eating disorders. That is not an over-reaction; it is the monitoring the researchers in this field are asking for and largely not getting⁴. If your worry is more about what your body is losing than what you are eating, our page on nutrient status on a GLP-1 is the more useful read.

Where this sits on the evidence scale

On binge eating: low-to-moderate, and better than I expected. One small randomised trial that missed significance on its own primary outcome, plus a rapid review of 25 studies in which binge-eating measures mostly improved or held steady, plus one prospective cohort of 31 initiators showing no deterioration. The direction of travel is consistent, but there is no adequately powered randomised trial of a modern GLP-1 in binge eating disorder, and the one drug with an actual regulatory indication for the condition is a different medicine entirely.

On restrictive eating disorders: essentially nil, and the gap is the story. A scoping review searching six databases found nine studies in the world on GLP-1 use in people with current or past eating disorders. What exists beyond that is one adolescent case report and a clinical argument about mechanism. Nobody can tell you the rate at which this happens, who it happens to, or how to spot it early — which is precisely why the field's own leading commentary is calling for routine screening rather than publishing reassurance.

The practical consequence: this is a page where the absence of research should change what you do. With most subjects on this site, thin evidence means proceed and monitor. Here, thin evidence plus a plausible harm mechanism means the screening conversation happens first, and a clinician — not a prescriber's questionnaire — makes the call.